List of Savella drug patents
Savella is owned by Allergan.
Savella contains Milnacipran Hydrochloride.
Savella has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Savella are:
- US6602911
Savella was authorised for market use on 14 January, 2009.
Savella is available in tablet;oral dosage forms.
Savella can be used as management of fibromyalgia, management of fibromyalgia (fm).
The generics of Savella are possible to be released after 19 September, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6602911 | ALLERGAN | Methods of treating fibromyalgia |
Jan, 2023
(13 days ago) | |
| US7994220 | ALLERGAN | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(6 years from now) | |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic